Clinical Liver Transplantation

American Journal of Transplantation

Volumn 1, Issue 1, 2001, Pages 18-20

  Roberts, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interferon; Liver transplantation; Living donor; MELD; Peginterferon

Indexed keywords

ADULT; ARTICLE; DONOR; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR;

ADULT; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; TISSUE DONORS;

EID: 0035342092     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2001.010105.x     Document Type: Article

References (8)

1. Marcos M. Right-lobe living donor liver transplantation. Liver Transpl 2000; 6: S59-S63.
2. Broelsch CE, Malagó M, Testa G, Gamazo CV. Living donor liver transplantation in adults: outcome in Europe. Liver Transpl 2000; 6: S64-S65.
3. Todo S, Furukawa H, Jin MB, Shimamura T. Living donor liver transplantation in adults: outcome in Japan. Liver Transpl 2000; 6: S66-S72.
4. Burroughs AK. Posttransplantation prevention and treatment of recurrent hepatitis C. Liver Transpl 2000; 6: S35-S40.
5. Heathcote EJ, Shiffman ML, Cooksley WGE et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-1680.
6. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
7. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871.
8. Mathematical models in chronic liver disease. The MELD model. http:// www.mayo.edu/int-med/gi/model/mayomodl-5.htm